ACADIA Pharmaceuticals is trading at $20.98, up 4.02% in pre-market, with no clear company-specific catalyst identified.
- The latest company-specific item was an investor-law-firm investigation announced October 27 concerning earlier remlifanserin trial results; it was not a positive development.
- Wall Street Zen’s reported Buy upgrade may be supportive, but available coverage does not establish that it caused the move.
- Quarterly results are scheduled for November 4; current pre-market volume information was unavailable.